Workflow
Mirum(MIRM)
icon
Search documents
Mirum(MIRM) - 2024 Q1 - Quarterly Results
2024-05-08 20:04
FOSTER CITY, Calif. – May 8, 2024 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2024 and provided a business update. "In the first quarter, we made great progress across a number of our strategic objectives that support both the near- and long-term growth of Mirum while maintaining a strong financial position," said Chris Peetz, chief executive officer at Mirum. "Our commercial business is performing well, and we saw continued growth in demand for LIVMARLI g ...
Mirum(MIRM) - 2023 Q4 - Annual Report
2024-03-15 21:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | (S ...
Mirum(MIRM) - 2023 Q4 - Earnings Call Transcript
2024-02-29 01:57
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Conference Call February 28, 2024 5:00 PM ET Company Participants Andrew McKibben - Vice President-Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Lili Nsongo - Leerink Partners Brian Skorney - Baird Ed Arce - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. Thank you fo ...
Mirum(MIRM) - 2023 Q3 - Quarterly Report
2023-11-02 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Indicat ...
Mirum(MIRM) - 2023 Q2 - Quarterly Report
2023-08-07 10:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | ...
Mirum(MIRM) - 2023 Q2 - Earnings Call Transcript
2023-08-05 15:42
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining. I would like to wel ...
Mirum(MIRM) - 2023 Q2 - Earnings Call Presentation
2023-08-04 17:17
Genetic disease leading to bile acid build-up and progressive liver damage 1 in every 50,000 to 100,000 births in the US and Europe This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our pending acquisition of CHOLBAM and CHENODAL and the ...
Mirum(MIRM) - 2023 Q1 - Earnings Call Transcript
2023-05-07 11:42
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President & Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Mani Foroohar - SVB Securities Ryan Deschner - Raymond James Operator Operator Ladies and gentlemen, welcome to the Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results ...
Mirum(MIRM) - 2023 Q1 - Quarterly Report
2023-05-04 20:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) ...
Mirum(MIRM) - 2022 Q4 - Earnings Call Transcript
2023-03-09 03:40
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney ...